Abstract
All current treatments for rectal cancer come with a price to pay, namely, the risk for over - and undertreatment based on current treatment decisions leading to sometimes even unnecassary toxicities. Thus, it would further improve the results of both treatment outcome and quality of life, if we could better tailor the treatment for rectal cancer based on validated biochemical and molecular biological factors. It is clear that several already known tumor biological features have an important impact on the individual tumor responses to certain treatments. Thus, detection and analysis of these biomarkers will ultimately lead to better treatment decisions in all parts of the current treatment algorithm. However, most studies so far have been rather limited in its attempts to identify biomarker based predictors for e.g. response to CRT, surgical decisions and systemic therapy. Six genetic biomarkers were identified with the potential of being predictive in the outcome after CRT, like p53, EGFR, TYMS, Ki-67, p21 and bax-bcl-2. TYMS expression measurements seem to be worthwhile to further study in future trials, while survivin showed mostly conflicting results and gene expression profiles with microarrays need further validation with larger patient groups. Nevertheless, there is great interest in the identification of biochemical and molecular biological factors in treatment decision making and many promising developments are on the way, like whole genome DNA, RNA analysis, multiple mutation testing, full sequencing and the association of genotype with phenotype. However, before the first successful biomarker development can been finalized and implemented clinically, several collaborations and consecutively external validations still need to be completed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adelstein BA, Dobbins TA, Harris CA et al (2011) A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer. Jun;47(9):1343–1354
Bosset JF, Collette L, Calais G et al (2006) ChemoÂtherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
Bujko K, Glynne-Jones R, Bujko M (2010) Adjuvant chemotherapy for rectal cancer. Ann Oncol. Dec;21(12):2443
Grimminger PP (2010) XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 164:e61–e66
Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011(29):1261–1270
Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646
Kim K, Chie EK, Wu HG et al (2011) High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. Aug;26(8):1019–1023
Koeberle D, Burkhard R, von Moos R et al (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98:1204–1209
Kuremsky JG (2009) Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673–688
Lamas MJ, Duran G, Gomez A et al (2012) X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys. Jan 1;82(1):138–144
Lammering G (2005) Molecular predictor and promising target: will EGFR now become a star in radiotherapy? Radiother Oncol 74:89–91
Lange MM, Maas CP, Marijnen CA et al (2008) Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 95:1020–1028
Leong KJ, Wei W, Tannahill LA et al (2011) Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Br J Surg 98:724–734
Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. Dec 10;29(35):4633–4640
Marijnen CA, Nagtegaal ID, Klein Kranenbarg E et al (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976–1984
McDowell MT (2009) Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. Int J Colorectal Dis 24:1261–1269
Páez D et al (2011) Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, Âepidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys 81:1319–1327, Epub 2011 May 11
Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients– a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206
Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580–587
Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609–618
Pucciarelli S, Del Bianco P, Efficace F et al (2011) Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg 253:71–77
Radu C, Berglund A, Påhlman L et al (2008) Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 87:343–349
Rasheed S, Harris AL, Tekkis PP et al (2009) Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer. Pathol Res Pract 205:1–9
Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. Jan 20;28(3):466–474. Epub 2009 Dec 14
Rödel F (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426–435
Rutten HJ, den Dulk M, Lemmens VE et al (2008) Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9:494–501
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
Stephens RJ, Thompson LC, Quirke P et al (2010) Impact of short-course preoperative radiotherapy for rectal cancer patients’ quality of life: data from the medical research council CR07/national cancer institute of Canada clinical trials group C016 randomized clinical trial. J Clin Oncol 28:4233–4239
Swellengrebel HA, Marijnen CA, Verwaal VJ et al (2011) Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 98:418–426
Tol J, Dijkstra JR, Vink-Börger ME, et al (2010) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. Aug;14(8):2122–2131
Tan BR (2011) Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 29:875–883
Valentini V, Van Stiphout RGPM, Lammering G et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29:3163–3172
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lammering, G., Buijsen, J. (2012). What Biochemical and Molecular Biological Factors Have Greater Relevance to Treatment Decisions?. In: Valentini, V., Schmoll, HJ., van de Velde, C. (eds) Multidisciplinary Management of Rectal Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25005-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-25005-7_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25004-0
Online ISBN: 978-3-642-25005-7
eBook Packages: MedicineMedicine (R0)